Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Cannabis induced dopamine release: an in-vivo SPECT study.

Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG.

Psychiatry Res. 2001 Oct 1;107(3):173-7.

PMID:
11566433
2.

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB.

Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40.

3.

Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms.

Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD.

Biol Psychiatry. 2014 Mar 15;75(6):470-8. doi: 10.1016/j.biopsych.2013.05.027. Epub 2013 Jun 29.

PMID:
23820822
4.

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL.

J Psychiatr Res. 2000 Jan-Feb;34(1):35-43.

PMID:
10696831
5.

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M.

Am J Psychiatry. 1998 Jun;155(6):761-7.

PMID:
9619147
6.

Influence of motor activity on striatal dopamine release: A study using iodobenzamide and SPECT.

Larisch R, Schommartz B, Vosberg H, Müller-Gärtner HW.

Neuroimage. 1999 Sep;10(3 Pt 1):261-8.

PMID:
10458941
7.

Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study.

Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH; SPECT study.

Am J Psychiatry. 2004 Aug;161(8):1496-8.

PMID:
15285982
8.

Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.

Schmitt GJ, Frodl T, Dresel S, la Fougère C, Bottlender R, Koutsouleris N, Hahn K, Möller HJ, Meisenzahl EM.

Eur Arch Psychiatry Clin Neurosci. 2006 Mar;256(2):115-21. Epub 2005 Nov 15.

PMID:
16284713
9.
10.

Cannabis and psychosis: an update on course and biological plausible mechanisms.

Linszen D, van Amelsvoort T.

Curr Opin Psychiatry. 2007 Mar;20(2):116-20. Review.

PMID:
17278907
11.

Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naïve schizophrenic patients.

Schmitt GJ, la Fougère C, Dresel S, Frodl T, Hahn K, Möller HJ, Meisenzahl EM.

Schizophr Res. 2008 Apr;101(1-3):133-41. Epub 2007 Dec 20.

PMID:
18083348
12.

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M.

Biol Psychiatry. 2000 Oct 1;48(7):627-40.

PMID:
11032974
13.

[99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system in Tourette syndrome.

Hwang WJ, Yao WJ, Fu YK, Yang AS.

Psychiatry Res. 2008 Feb 28;162(2):159-66. doi: 10.1016/j.pscychresns.2007.04.006.

PMID:
18248965
14.

Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia.

Yang YK, Yeh TL, Chiu NT, Lee IH, Chen PS, Lee LC, Jeffries KJ.

Psychiatry Res. 2004 Sep 15;131(3):209-16.

PMID:
15465290
15.

The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study.

Bloomfield MA, Morgan CJ, Kapur S, Curran HV, Howes OD.

Psychopharmacology (Berl). 2014 Jun;231(11):2251-9. doi: 10.1007/s00213-014-3523-4. Epub 2014 Apr 3.

PMID:
24696078
16.

Further human evidence for striatal dopamine release induced by administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum.

Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR.

Psychopharmacology (Berl). 2015 Aug;232(15):2723-9. doi: 10.1007/s00213-015-3915-0. Epub 2015 Mar 25.

17.

[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.

Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ.

Am J Psychiatry. 1996 Feb;153(2):183-90.

PMID:
8561197
18.

Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia.

Gevonden M, Booij J, van den Brink W, Heijtel D, van Os J, Selten JP.

JAMA Psychiatry. 2014 Dec 1;71(12):1364-72. doi: 10.1001/jamapsychiatry.2014.1325.

PMID:
25271822
19.

In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.

Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K.

Eur J Nucl Med. 1999 Aug;26(8):862-8.

PMID:
10436199
20.

SPECT imaging of striatal dopamine release after amphetamine challenge.

Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, et al.

J Nucl Med. 1995 Jul;36(7):1182-90.

Supplemental Content

Support Center